I seem to recall someone here making some somewhat disparaging comments about them, but I don't recall the occasion.
Note they are not competing with RNA at all - they are going after mutually disjoint subsets of the disease.
I actually first got interested in them because of some interesting late-stage preclinical work they are doing related to colon cancer stem cells - but they didn't cover that at all at JPM.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.